Fang Jiali, Genco Matthew, Caskey Rachel N
Department of Medicine, University of Illinois at Chicago, Chicago, USA.
Eur J Case Rep Intern Med. 2020 Oct 26;7(11):001943. doi: 10.12890/2020_001943. eCollection 2020.
To describe a patient who developed euglycaemic diabetic ketoacidosis (DKA) in the setting of SGLT2 inhibitor use precipitated by COVID-19.
A 52-year-old male with type II diabetes on empagliflozin and no history of DKA presented with symptoms of COVID-19 as well as laboratory findings consistent with euglycaemic DKA. His hospital course was complicated by recurrent episodes of euglycaemic DKA as well as hyperglycaemic DKA.
GLT2 inhibitors should be held as early as possible in COVID-19 cases due to the risk of euglycaemic DKA. These patients should also have more intense glucose monitoring.
COVID-19 can precipitate euglycaemic DKA in diabetic patients taking SGLT2 inhibitors.Clinicians should be cognizant that the effects of SGLT2 inhibitors can persist for more than 72 hours after the last dose.Diabetic patients with COVID-19 require closer strict glucose monitoring to reduce the risk of DKA.
描述一名在使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的情况下，因新型冠状病毒肺炎（COVID-19）诱发正常血糖性糖尿病酮症酸中毒（DKA）的患者。
一名52岁男性，患有II型糖尿病，正在服用恩格列净，既往无DKA病史，出现了COVID-19症状以及与正常血糖性DKA相符的实验室检查结果。他的住院过程因反复出现正常血糖性DKA以及高血糖性DKA而变得复杂。
由于存在正常血糖性DKA的风险，在COVID-19病例中应尽早停用SGLT2抑制剂。这些患者还应加强血糖监测。
COVID-19可在服用SGLT2抑制剂的糖尿病患者中诱发正常血糖性DKA。临床医生应认识到，SGLT2抑制剂的作用在最后一剂后可持续超过72小时。患有COVID-19的糖尿病患者需要更密切严格的血糖监测，以降低DKA的风险。
